Drug Sponsors

Teva proposes to acquire Mylan for $82 per share in cash and stock

Wednesday, April 22, 2015 12:14 PM

Teva Pharmaceutical Industries has proposed to acquire all of the outstanding shares of Mylan in a transaction valued at $82 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company.

More... »

Mylan comments on recent bid speculation

Tuesday, April 21, 2015 07:51 AM

Mylan executive chairman Robert J. Coury has commented on recent media speculation about a takeover bid from Teva.

More... »

Merck chairman, CEO Kenneth C. Frazier becomes PhRMA board chairman

Friday, April 17, 2015 12:40 PM

Kenneth C. Frazier, chairman and CEO of Merck, was elected chairman of the board of the Wash. D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). At the board meeting, PhRMA’s president and CEO John J. Castellani announced he will be retiring Jan. 1, 2016. 

More... »

BioRestorative Therapies opens new headquarters, lab facility in New York

Wednesday, April 15, 2015 12:42 PM

BioRestorative Therapies (BRT), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has relocated its corporate, administrative and laboratory operations to Melville, Long Island, N.Y.

More... »

Incyte to establish European headquarters in Geneva

Wednesday, April 15, 2015 12:41 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, will establish the new headquarters of Incyte Europe in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000-square-foot facility by mid-2015.

More... »

Cipher Pharmaceuticals enters U.S. market with Innocutis acquisition

Monday, April 13, 2015 12:21 PM

Cipher Pharmaceuticals, a Canada-based specialty pharmaceutical dermatology company, has acquired Innocutis Holdings, a Charleston, S.C.-based, privately held specialty dermatology company, for $45.5 million in cash.

More... »

Mylan notifies Perrigo of HSR filing regarding proposed acquisition

Monday, April 13, 2015 12:20 PM

Mylan, a global generics and specialty pharmaceutical company, has provided Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, with notice of its filing of the pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.

More... »

Roche acquires CAPP Medical, strengthens oncology translational research pipeline

Monday, April 13, 2015 12:18 PM

Roche has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and located in Palo Alto, Calif., to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood.

More... »

Biotech companies raise record amount of capital in Q1

Monday, April 13, 2015 08:00 AM

By Ronald Rosenberg
CenterWatch Staff Writer

Although the financial market turbu­lence in the first quarter of 2015 scared some investors, it did not slow down public and private biotechnology companies from collectively raising a record-setting $14 billion—nearly 50% more than the total raised in the first quarter of 2014, which was consid­ered the high watermark for the industry.

More... »

Pfizer launches competitive grants program for cardiovascular disease research

Friday, April 10, 2015 01:21 PM

Pfizer has launched a new competitive grants program to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer's ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease.

More... »


July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs